Skip to main content

Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues.

Berg D, Langer R, Tran K, Walch A, Schuster T, Bronger H, Becker KF

Publication: Appl Immunohistochem Mol Morphol (2011) • Vol 19 • Page 300-5PMID: 21293257View on PubMed

Purpose

The purpose of this paper was to compare expression levels of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) by reverse phase protein microarray (RPPA) using protein extracted from archival formalin-fixed paraffin-embedded (FFPE) surgical excision specimens as well as core biopsy specimens.

Conclusion

Protein expression values for ER, PR, and HER2 were highly concordant between core biopsies and surgical excision specimens when expression was assessed by RPPA. In addition, RPPA results were highly concordant with immunohistochemistry (IHC) results for both types of specimens.

Studies (1)

Purpose

The purpose of this study was to compare HER2, ER, and PR protein expression in core biopsies and surgical excision specimens using RPPA. Additionally, RPPA results were compared with IHC results. FISH was used to further evaluate HER2 status of specimens scored as 2+ by IHC.

Summary of Findings

Absolute concordance rates between surgical specimens and core biopsies were 91.4% for HER2, 80% for ER, and 82.8% for PR. For HER2, 1/35 specimens was classified as HER2+ in the surgical specimen but HER2- in the core biopsy, while 2/35 specimens were HER2- in the surgical specimen but HER2+ in the core biopsy. For ER, 1/35 specimens was classified as ER+ in the surgical specimen but ER- in the core biopsy, while 6/35 specimens were ER- in the surgical specimen but ER+ in the core biopsy. For PR, 4/35 specimens were classified as PR+ in the surgical specimen but PR- in the core biopsy, while 2/35 specimens were PR- in the surgical specimen but PR+ in the core biopsy. Concordance rates of 100% and 94.2% were seen between RPPA and IHC for surgical specimens and core biopsies, respectively.

  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinReverse phase protein microarray
    ProteinImmunohistochemistry
    DNAFISH
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionMethod of tissue acquisition
    Core needle biopsy
    Surgical resection
    FISH SpecificTargeted nucleic acid
    HER2
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER2
    PR
    Reverse phase protein microarray SpecificTargeted peptide/protein
    ER
    HER2
    PR
    Reverse phase protein microarray SpecificTechnology platform
    Immunohistochemistry